This phase III study is comparing the effectiveness of different immunotherapies (ociperlimab, tislelizumab and durvalumab), combined with concurrent chemoradiation therapy, in people with previously untreated, locally advanced non-small cell lung cancerPhase 3, Randomized, Open Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Plus Concurrent Chemoradiotherapy (cCRT) Followed by Ociperlimab Plus Tislelizumab or Tislelizumab Plus cCRT Followed by Tislelizumab Versus cCRT Followed by Durvalumab in Previously Untreated, Locally Advanced, Unresectable Non-Small Cell Lung Cancer

Summary

Eligible participants will be randomly assigned to one of three arms. In Arm A (Experimental), participants will receive two cycles of ociperlimab (900mg intravenously [IV]) combined with tislelizumab (200mg IV) every 3 weeks (Q3W) with Concurrent Chemoradiotherapy (cCRT), followed by further treatment with ociperlimab (900mg IV) combined with tislelizumab (200mg IV) Q3W up to 1 year after the cCRT phase. In Arm B (Active Comparator), participants will receive tislelizumab (200mg IV Q3W) combined with cCRT, followed by further treatment with tislelizumab (200mg IV Q3W) up to 1 year after the cCRT phase. In Arm C, (Experimental), participants will receive two cycles of cCRT followed by treatment with durvalumab (10mg/kg IV) once every 2 weeks (Q2W) up to 1 year after the cCRT phase.

More information